This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A Further Examination of Pharmacy Benefit Managers Nicholas Saraceno, Editor March 29th 2024 Podcast Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drugprice transparency.
How Recent Executive Orders Impact the DrugPricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drugpricing and market access.
AI in value-based pricing and RWE generation AI has the potential to transform value-based pricing (VBP) by leveraging machine learning for dynamic pricing models that adjust drugprices based on real-world patient outcomes.
How Recent Executive Orders Impact the DrugPricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drugpricing and market access.
This pathway’s expanded use and shifting Centers for Medicare & Medicaid Services (CMS) policies are reshaping reimbursement practices and therapeutic equivalence standards for 505(b)(2) drugs. It is basically an essential copy, and the pharmaceuticalmanufacturer has to show bioequivalence to the reference product,” Soefje said. “If
4 ,5 Millions of Americans rely on medicines that are manufactured outside the United States, particularly from close and longstanding allies such as Ireland, Switzerland, and the United Kingdomcountries whose regulatory frameworks for pharmaceuticalmanufacturing mirror the high standards enforced domestically.
According to Trump, patients could see cost reductions of 30% to 80%, but experts question the feasibility and practicality of implementing such a policy within the complex United States drugpricing and supply system. Kennedy Jr, is permitted to develop a new rule that ties American drugprices to those of other nations.
In some cases, these events might be entirely unpredictable, forcing them to adapt product strategies with little to no advanced preparation. Disruptions such as pandemics and natural disasters pose a major challenge for hospitals. Luckily, intelligent medication management software can play a crucial role in responding to disruptions.
The industry's dependence on geopolitical stability and predictable trade relationships is increasingly critical for global pharmaceuticalmanufacturing. In such event, Sponsor reserves the right to award the prizes at random from among the eligible entries received up to the time of the impairment. Share your voice!
tariffs on imports from Mexico, Canada, and China have disrupted the pharmaceutical industry, prompting reshoring discussions. tariffs on imports from Mexico, Canada, and China have disrupted the pharmaceutical industry, prompting reshoring discussions. Timeline of key events Feb. 3 The 10% tariff on China remains in effect.
24 Hours in the Hub Still Matters More June 16, 2025 By Chris Dowd, ConnectiveRx Commentary Article Pharmaceutical Commerce Pharmaceutical Commerce - June 2025 Volume 20 Issue 3 Doubling down on patient access and support fundamentals will win out over Washington’s next move.
Key Takeaways A formal trade agreement between the US and EU introduces a 15% tariff on most EU exports, including pharmaceuticals, potentially costing the pharma sector $13 billion–$19 billion. Experts recommend stockpiling medications and using forecasting tools to navigate tariff uncertainty and mitigate potential supply disruptions.
A new state-of-the-art facility in Virginia will produce active pharmaceutical ingredients (APIs) for weight management and metabolic treatments, leveraging AI, automation, and data analytics. 2 He described it as being a “low tariff” that would slowly increase over the course of approximately a year.
Trump signed an executive order titled “Delivering Most-Favored-Nation Prescription DrugPricing to American Patients,” with the objective of lowering drugprices, namely on branded drug products, for American consumers. How Does DrugPricing in the US Compare With Other Countries? REFERENCES 1.
2 Although seen as restoring incentives for rare disease research, critics argue it perpetuates high pricing and industry-friendly policy. The OBBB expanded the list of drugs exempt from negotiation and delayed implementation of new price controls.
How the Rise in Self-Injectables Is Impacting PharmaceuticalManufacturing. Pharmaceutical Commerce. TekniPlex Healthcare Opens New Flagship Barrier Protection Systems Facility in Madison, Wisconsin. June 12, 2025. Accessed June 18, 2025. Robinson S. May 6, 2025. Accessed June 18, 2025. February 18, 2025.
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCIs new live video webinar: Whats Next for Retail Pharmacy: Data, Debate, and Disruption This event will be broadcast live on: Friday, June 20, 2025 12:00 p.m. to 1:30 p.m. Special Discounts For Teams!
After recently being blocked from implementing their own rebate models for the controversial 340B DrugPricing Program, which provides discounted medications to healthcare centers that serve low-income or uninsured patients, drugmakers will soon have the opportunity to voluntarily participate in a pilot that changes this dynamic.
Miranda McLaren June 30, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook When Donald Trump was elected the 47 th president of the United States of America, the outlook for pharmaceuticals was unclear, with 55% of North American industry professionals expecting negative repercussions when surveyed by GlobalData later that month.
June 18th 2025 Article The June issue of Pharmaceutical Commerce highlights the importance of embracing agility—and adaptable strategies—to better navigate industry challenges.
Manasi Vaidya August 1, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook President Trump has sent letters to several leading pharmaceuticalmanufacturers outlining steps they need to take in line with the administration’s Most Favored Nation policy to bring down drugprices in the US.
A new analysis of mid-year price hikes has found that, despite policy changes under the Inflation Reduction Act, drugprices are on the rise , STAT reports. Biden health officials are expected to reveal the initial list before the stock market opens Tuesday morning.
Bill Roth Key Takeaways Price hikes, not launch prices, drove the GTN bubble. The real driver of the gross-to-net (GTN) bubble was the pharmaceutical industry's ability to raise drugprices year after year—enabled by loopholes in PBM contracts—rather than high launch prices alone.
Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals DrugPricing Gene Therapy An article from FDA’s AI tool ‘Elsa’ is here, and the industry has questions The agency has provided only limited details about its AI pilot as it advances an “aggressive timeline” for the tool’s rollout.
This expansion continues a flawed policy that threatens innovation and jeopardizes patient access to critical treatments, including drugs vital for cancer treatment and popular new weight loss medications that have transformed the management of obesity and related conditions. What Will 2025 Mean for Medicare DrugPrice Setting Under the IRA?
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content